GLP-1 weight loss drugs show effectiveness at low starter doses, offering weight loss with fewer side effects compared to ...

Incretin-based therapies have an important role in the management of overweight and obesity; however, the devices currently used hinder the full potential for personalised medicine.1 ...

MagneINNO’s platform is built around high-purity, fully chelated, unbuffered magnesium glycinate rather than a single ...

In a press release issued today, 1 Metrohm USA announced the launch of OMNIS IC, a new ion chromatography (IC) system built ...

No single method covers everything. Public water systems in the United States must follow approved analytical methods and ...

Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly. First European patient ...

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...

Management highlighted the inclusion of nafamostat as an acceptable regional anticoagulant in the 2026 KDIGO draft guidelines, marking the first time the drug has been recommended by this global body.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

Background Effective decongestion is a key therapeutic goal during hospitalisation for acute heart failure (HF), but the ...

PMA: Premarket Approval, the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices.